Literature DB >> 26045050

Expansion of the hematopoietic stem cell compartment is necessary but not sufficient for gain-of-function mutant p53 R248Q to accelerate lymphomagenesis.

A R Yallowitz1, W Hanel1, U M Moll1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26045050      PMCID: PMC4495365          DOI: 10.1038/cdd.2015.63

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  7 in total

1.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Authors:  Cyril Quivoron; Lucile Couronné; Véronique Della Valle; Cécile K Lopez; Isabelle Plo; Orianne Wagner-Ballon; Marcio Do Cruzeiro; Francois Delhommeau; Bertrand Arnulf; Marc-Henri Stern; Lucy Godley; Paule Opolon; Hervé Tilly; Eric Solary; Yannis Duffourd; Philippe Dessen; Hélène Merle-Beral; Florence Nguyen-Khac; Michaëla Fontenay; William Vainchenker; Christian Bastard; Thomas Mercher; Olivier A Bernard
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

Review 2.  Clonal evolution of acute leukemia genomes.

Authors:  M Jan; R Majeti
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

Review 3.  The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.

Authors:  Vinod Pant; Alfonso Quintás-Cardama; Guillermina Lozano
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

4.  Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia.

Authors:  Yoshikane Kikushige; Fumihiko Ishikawa; Toshihiro Miyamoto; Takahiro Shima; Shingo Urata; Goichi Yoshimoto; Yasuo Mori; Tadafumi Iino; Takuji Yamauchi; Tetsuya Eto; Hiroaki Niiro; Hiromi Iwasaki; Katsuto Takenaka; Koichi Akashi
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

5.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.

Authors:  W Hanel; N Marchenko; S Xu; S Xiaofeng Yu; W Weng; U Moll
Journal:  Cell Death Differ       Date:  2013-03-29       Impact factor: 15.828

6.  Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Authors:  E M Alexandrova; A R Yallowitz; D Li; S Xu; R Schulz; D A Proia; G Lozano; M Dobbelstein; U M Moll
Journal:  Nature       Date:  2015-05-25       Impact factor: 49.962

7.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre.

Authors:  Jasper de Boer; Adam Williams; George Skavdis; Nicola Harker; Mark Coles; Mauro Tolaini; Trisha Norton; Keith Williams; Kathleen Roderick; Alexandre J Potocnik; Dimitris Kioussis
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.